GbE was shown to exhibit a wide range of pharmaceutical activities on obesity-related conditions, including HFD-induced obesity, diabetes mellitus, and non-alcoholic fatty liver disease [16,17,18]. This evidence concerns the gene GBE1 and Obesity.